Matches in Wikidata for { <http://www.wikidata.org/entity/Q64710425> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- Q64710425 description "assaig clínic" @default.
- Q64710425 description "clinical trial" @default.
- Q64710425 description "clinical trial" @default.
- Q64710425 description "clinical trial" @default.
- Q64710425 description "clinical trial" @default.
- Q64710425 description "ensaio clínico" @default.
- Q64710425 description "ensayo clínico" @default.
- Q64710425 description "ensayu clínicu" @default.
- Q64710425 description "essai clinique" @default.
- Q64710425 description "klinisch onderzoek" @default.
- Q64710425 description "клінічне випробування" @default.
- Q64710425 name "Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17" @default.
- Q64710425 type Item @default.
- Q64710425 label "Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17" @default.
- Q64710425 prefLabel "Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17" @default.
- Q64710425 P1132 Q64710425-2C73BDFA-5805-4FDE-8CFA-D99AD80188F0 @default.
- Q64710425 P1476 Q64710425-417A9B6D-7FD7-4039-9E31-782BD14F4B05 @default.
- Q64710425 P17 Q64710425-2ADF5187-FD29-4611-8C22-99AE9C5BFC2E @default.
- Q64710425 P17 Q64710425-3CA62FE6-D22E-46F9-815D-734D5547E32D @default.
- Q64710425 P17 Q64710425-500BDBBB-DCA6-4DE9-B18F-885D9853EEC1 @default.
- Q64710425 P17 Q64710425-59E3792D-70D8-4BBE-9C65-E16E6E7D4D30 @default.
- Q64710425 P17 Q64710425-828AB27A-F94C-46BE-8E06-CE43BBF1F45F @default.
- Q64710425 P17 Q64710425-A7CA1F96-D282-4953-AF34-7506CB3FDA79 @default.
- Q64710425 P17 Q64710425-C2A74CB0-9D7A-4CB5-B12A-7118BCC5720F @default.
- Q64710425 P17 Q64710425-E53A7519-DC94-41D2-B06A-D138BADCC019 @default.
- Q64710425 P17 Q64710425-EFA3BD9D-5DD2-410A-8739-D149D04F168E @default.
- Q64710425 P2899 Q64710425-DDC3FBCE-0656-4488-B5D9-A9776C16496D @default.
- Q64710425 P3098 Q64710425-8F1056CB-D4E4-4E52-97C4-DD46BEF63F14 @default.
- Q64710425 P31 Q64710425-69264B56-BB96-4947-B6D3-6EFAC50D5522 @default.
- Q64710425 P4135 Q64710425-5D0E5573-6461-41B2-8329-88DFD52FC2C0 @default.
- Q64710425 P4844 Q64710425-E5414544-9809-4288-A985-46CA85534A83 @default.
- Q64710425 P580 Q64710425-E258E9B9-D6A2-4F51-8588-12DF0E151A08 @default.
- Q64710425 P582 Q64710425-D82F8309-951D-4144-AB12-E2414F6FC053 @default.
- Q64710425 P6099 Q64710425-F6E00B82-9255-4BF6-8D53-6E7077AEC65B @default.
- Q64710425 P6153 Q64710425-535E56BF-E87A-4216-A7C1-432B863BDF70 @default.
- Q64710425 P6153 Q64710425-EC7A6C7D-55E3-41A2-8877-68638D076179 @default.
- Q64710425 P8363 Q64710425-F9DF2B84-C03B-44B4-BC72-5E3668154E36 @default.
- Q64710425 P1132 "+276" @default.
- Q64710425 P1476 "A Phase III, Double-blind, Placebo-controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention- Deficit/Hyperactivity Disorder (ADHD)" @default.
- Q64710425 P17 Q142 @default.
- Q64710425 P17 Q145 @default.
- Q64710425 P17 Q183 @default.
- Q64710425 P17 Q28 @default.
- Q64710425 P17 Q30 @default.
- Q64710425 P17 Q31 @default.
- Q64710425 P17 Q34 @default.
- Q64710425 P17 Q36 @default.
- Q64710425 P17 Q38 @default.
- Q64710425 P2899 "+6" @default.
- Q64710425 P3098 "NCT00784654" @default.
- Q64710425 P31 Q30612 @default.
- Q64710425 P4135 "+17" @default.
- Q64710425 P4844 Q27289243 @default.
- Q64710425 P580 "2009-01-01T00:00:00Z" @default.
- Q64710425 P582 "2011-10-01T00:00:00Z" @default.
- Q64710425 P6099 Q42824827 @default.
- Q64710425 P6153 Q30269691 @default.
- Q64710425 P6153 Q7690326 @default.
- Q64710425 P8363 Q78089383 @default.